{"id":63663,"date":"2026-04-21T23:22:41","date_gmt":"2026-04-21T15:22:41","guid":{"rendered":"https:\/\/flcube.com\/?p=63663"},"modified":"2026-04-21T23:22:42","modified_gmt":"2026-04-21T15:22:42","slug":"eli-lilly-to-acquire-kelonia-therapeutics-for-7-billion-to-secure-in-vivo-car-t-platform-targeting-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63663","title":{"rendered":"Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion to Secure In Vivo CAR-T Platform Targeting Multiple Myeloma"},"content":{"rendered":"\n

Eli Lilly and Company<\/strong> (NYSE: LLY<\/a>) has agreed to acquire Kelonia Therapeutics<\/strong>, a clinical-stage biotechnology firm pioneering in vivo gene delivery<\/strong>, in a deal valued at $7 billion<\/strong>. The transaction includes an upfront payment of $3.25 billion<\/strong> and up to $3.75 billion in milestone payments<\/strong> tied to clinical, regulatory, and commercial achievements. The acquisition\u2014expected to close in H2 2026<\/strong>\u2014gives Lilly full control of KLN-1010<\/strong>, a potentially transformative single-dose intravenous gene therapy<\/strong> for relapsed\/refractory multiple myeloma<\/strong>.<\/p>\n\n\n\n

Deal Structure & Strategic Rationale<\/h2>\n\n\n\n
Component<\/th>Detail<\/th><\/tr><\/thead>
Total Value<\/strong><\/td>Up to $7 billion<\/strong> ($3.25B upfront + $3.75B milestones)<\/td><\/tr>
Target Asset<\/strong><\/td>KLN-1010<\/strong> \u2013 in vivo-generated anti-BCMA CAR-T therapy<\/td><\/tr>
Mechanism<\/strong><\/td>Single IV infusion delivers genetic payload to generate functional CAR-T cells inside the body<\/strong>, eliminating need for ex vivo manufacturing<\/td><\/tr>
Key Advantages<\/strong><\/td>\u2013 No leukapheresis or cell processing
\u2013 No preconditioning chemotherapy
\u2013 Potential for outpatient administration<\/td><\/tr>
Clinical Validation<\/strong><\/td>Early data presented at ASH 2025 Plenary Session<\/strong> showed durable responses<\/strong> and favorable tolerability<\/strong> in heavily pretreated patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Multiple myeloma affects over 160,000 patients globally<\/strong>, with most eventually relapsing after standard therapies. Current ex vivo CAR-T products<\/strong> (e.g., Abecma, Carvykti) require complex logistics, weeks-long manufacturing, and toxic lymphodepletion\u2014barriers KLN-1010 aims to overcome.<\/p>\n\n\n\n

Technology Disruption Potential<\/h2>\n\n\n\n

Kelonia\u2019s platform represents a paradigm shift<\/strong> in cell therapy:<\/p>\n\n\n\n